JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, T. J.
Right arrow Articles by Smith, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, T. J.
Right arrow Articles by Smith, J. E.

Vol. 294, Issue 3, 975-982, September 2000

Antagonism of delta 2-Opioid Receptors by Naltrindole-5'-isothiocyanate Attenuates Heroin Self-Administration but Not Antinociception in Rats1

Thomas J. Martin, Susy A. Kim, David G. Cannon, Glen M. Sizemore, Di Bian, Frank Porreca and James E. Smith

Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina (T.J.M., S.A.K., D.G.C., G.M.S., J.E.S.); and Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, Arizona (D.B., F.P.)

delta -Opioid receptors have been implicated in reinforcement processes and antagonists are available that produce long-lasting and selective antagonism of delta -opioid receptors in vivo. This experiment assessed the contribution of delta -opioid receptors to the antinociceptive and reinforcing properties of heroin. The effects of the irreversible delta -antagonist naltrindole-5'-isothiocyanate (5'-NTII) were evaluated on heroin self-administration and hot-plate antinociception in rats. 5'-NTII (10 nmol i.c.v.) shifted the dose-response curve for heroin self-administration downward, increasing the A50 values on the ascending and descending limbs by approximately 0.5 log units and decreasing the maximum by 33%. 5'-NTII (40 nmol i.c.v.) shifted both limbs of the heroin self-administration dose-effect curve 1.2 log units to the right and decreased the maximum by 90%. Heroin self-administration gradually returned to baseline levels over 7 or 17 days after administration of 10 or 40 nmol 5'-NTII, respectively. 5'-NTII (40 nmol i.c.v.) decreased the self-administration of 0.17 mg/infusion cocaine by 40% while having no effect on responding maintained by 0.33 or 0.67 mg/infusion. 5'-NTII attenuated the antinociceptive effects of deltorphin (delta 2) in a dose-dependent manner while having no effect on antinociception elicited after i.c.v. administration of [D-Pen2,D-Pen5]-enkephalin (delta 1) or [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (µ). In addition, the antinociceptive effects of heroin were not significantly affected by 5'-NTII (40 nmol i.c.v.). Therefore, 5'-NTII can attenuate the reinforcing effects of heroin at doses that do not affect its antinociceptive effects. Long-acting delta 2-opioid antagonists may be beneficial in the treatment of heroin dependence or as adjuncts to reduce the abuse liability of opioid analgesics.


1 This study was supported by the National Institute on Drug Abuse of the National Institutes of Health through Grants DA-00247 (to T.J.M.), DA-06284 (to F.P.), DA-08657 (to F.P.), DA-01999 (to J.E.S.), DA-06634 (to J.E.S.), and DA-12489 (to J.E.S.). F.P. is the recipient of a Research Scientist Development Award (KO2 DA-00185). J.E.S. is the recipient of a Senior Scientist Development Award (KO5 DA-00114).


0022-3565/00/2943-0975$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Drakenberg, A. Nikoshkov, M. C. Horvath, P. Fagergren, A. Gharibyan, K. Saarelainen, S. Rahman, I. Nylander, G. Bakalkin, J. Rajs, et al.
From the Cover: {micro} Opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers
PNAS, May 16, 2006; 103(20): 7883 - 7888.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. M. Thompson, H. Wojno, E. Greiner, E. L. May, K. C. Rice, and D. E. Selley
Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at {micro}- and {delta}-Opioid Receptors
J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 547 - 554.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Navarro, M. R. A. Carrera, W. Fratta, O. Valverde, G. Cossu, L. Fattore, J. A. Chowen, R. Gomez, I. del Arco, M. A. Villanua, et al.
Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration
J. Neurosci., July 15, 2001; 21(14): 5344 - 5350.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.